Terri Lynn Parker MD

Hematologic Oncology

Assistant Professor, Comprehensive Cancer Center, Yale University School of Medicine

20 York StYale-New Haven HospitalNew Haven, CT 06510
Phone+1 203-200-4363
Fax+1 203-785-4116

Dr. Parker is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Parker's full profile Already have an account?

Summary

Dr. Terri Parker is an Assistant Professor of Medicine in the Section of Hematology at Yale School of Medicine, based in New Haven, CT. She specializes in oncology, with a subspecialty in hematologic oncology. Her academic background includes a fellowship in Hematology and Medical Oncology at Yale-New Haven Medical Center. Dr. Parker's expertise encompasses amyloidosis, hematologic oncology, and multiple myeloma. She is actively engaged in clinical research, having published several papers in reputable journals and participated in multiple clinical trials involving multiple myeloma. Her contributions to medical education were recognized with the David S. Fischer Teaching Award from Yale Cancer Center. She also holds several CMS Meaningful Use Stage Certifications.

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Uconn School Of Medicine2008 - 2009
University of ConnecticutResidency, Internal Medicine, 2005 - 2008
St. George's University School of MedicineClass of 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 2008 - 2027
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017

Clinical Trials

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
COMPLETED
PHASE1, PHASE2
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2013 Dec 06
ACTIVE_NOT_RECRUITING
PHASE3
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma Start of enrollment: 2016 Aug 10
COMPLETED
PHASE3

Publications & Presentations

PubMed

Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma Across a Regional Academic-Community Network.
Poy Theprungsirikul, Amer Al-Musa, Noffar Bar, Sabrina L Browning, Terri Parker
Cancers. 2026-06-11
1 citations
Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged 'early' after intensive induction.
Cameron J Hunter, Wei Cheng, Jan Philipp Bewersdorf, Prajwal Boddu, Sabrina Browning
Leukemia & Lymphoma. 2026-01-01
3 citations
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702).
Terri L Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J Landau, Erica L Campagnaro
Blood. 2025-11-20

Abstracts/Posters

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Terri L Parker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
Terri L Parker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Cutaneous toxicity of pralatrexate in cutaneous and peripheral T-cell lymphoma
Parker TL, Barbarotta L, Girardi M, and Foss F., American Society of Hematology Annual Meeting, Atlanta, GA, 12/2012

Committees

Member, Scientific Protocol Review Committee at Smilow Cancer Hospital 2015 - Present
Member, Laboratory Formulary Committee at Yale New Haven Hospital 2014 - Present
Member, Smilow Ambulatory Care Committee 2013 - Present
Member, Transfusion and Tissue Banking Committee at Yale New Haven Hospital 2013 - Present
Member, Faculty Advisory Committee at Yale School of Medicine 2015 - 2017